Sugi Predict

Sugi Predict / Compounds / SCHEMBL371600

SCHEMBL371600

SCHEMBL371600

COc1cc2nccc(Oc3cc4sc(NC(=O)Cc5cc(C(F)(F)F)ccc5Cl)nc4cc3F)c2cc1OC

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 7/20 0.53
▸ CSNK1D P48730 11/20 0.53
▸ CSF1R P07333 1/20 0.49
▸ RET P07949 1/20 0.49
▸ PDGFRB P09619 1/20 0.49
▸ KIT P10721 1/20 0.49
▸ PDGFRA P16234 1/20 0.49
▸ DDR1 Q08345 1/20 0.49
▸ KDR P35968 2/20 0.44
▸ HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693528 1.00 MET (0.53) METCSNK1DCSF1RRETPDGFRB
SCHEMBL371920 0.87 MET (0.60) METCSNK1DCSF1RRETPDGFRB
SCHEMBL29693525 0.87 MET (0.62) METCSNK1DKDR
SCHEMBL371540 0.87 MET (0.62) METCSNK1DKDR
SCHEMBL371825 0.82 MET (0.76) METCSNK1DCSF1RPDGFRBKIT
SCHEMBL371622 0.78 MET (0.64) METKDR
SCHEMBL371541 0.78 MET (0.46) METKDR
SCHEMBL2189472 0.78 MET (0.87) METCSNK1DCSF1RPDGFRBKIT
SCHEMBL15580183 0.77 MET (0.65) METCSNK1DPDGFRBKITPDGFRA
SCHEMBL20525805 0.76 RIPK1 (0.55) METCSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
US-20110172241-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2011-07-14 — — US claimed
US-20090270410-A1 BENZAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2009-10-29 — — US claimed
US-7576090-B2 e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent 4SC AG (DE) 2009-08-18 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
EP-1833823-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2007-09-19 — — EP claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
WO-2006069740-A1 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-07-06 — — WO claimed
US-20060142570-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-29 — — US claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
WO-2006069740-A1 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-07-06 — — WO disclosed
US-20060142570-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885CSNK1D 900/4885CSF1R 164/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885CSNK1D 900/4885CSF1R 164/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885CSNK1D 656/4885CSF1R 245/4885
US-20060142570-A1 Benzazole analogues and uses thereof CYP3A5, CYP3A7, CYP3A43 MET 4526/4885CSNK1D 1578/4885CSF1R 3901/4885
US-20110172241-A1 Benzazole analogues and uses thereof CYP3A5, CYP3A7, CYP3A43 MET 4526/4885CSNK1D 1578/4885CSF1R 3901/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885CSNK1D 900/4885CSF1R 164/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885CSNK1D 900/4885CSF1R 164/4885
US-20090270410-A1 BENZAZOLE ANALOGUES AND USES THEREOF CYP3A5, CYP3A7, CYP3A43 MET 4512/4885CSNK1D 1636/4885CSF1R 3947/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885CSNK1D 656/4885CSF1R 245/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885CSNK1D 900/4885CSF1R 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.